Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Short Communications

CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer

Sarah J. Plummer, David V. Conti, Pamela L. Paris, Anthony P. Curran, Graham Casey and John S. Witte
Sarah J. Plummer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David V. Conti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela L. Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony P. Curran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Casey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John S. Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Genotype and haplotype frequencies of CYP3A4 and CYP3A5 variants in prostate cancer cases and sibling controlsa

    Genotype/HaplotypeAllelesAll SubjectsbCaucasiansAfrican-Americans
    CasesControlsCasesControlsCasesControls
    CYP3A4 c
    *1A/*1A376 (87%)402 (86%)362 (93%)391 (92%)11 (29%)8 (21%)
    *1A/*1B39 (9%)52 (11%)24 (6%)34 (8%)13 (34%)16 (42%)
    *1B/*1B18 (4%)15 (3%)4 (1%)1 (0.2%)14 (37%)14 (37%)
    CYP3A5 c
    *3/*3345 (78%)366 (76%)337 (85%)359 (82%)6 (16%)5 (13%)
    *3/*178 (18%)94 (20%)57 (14%)75 (17%)18 (47%)16 (42%)
    *1/*117 (4%)20 (4%)3 (0.8%)3 (0.7%)14 (37%)17 (45%)
    CYP3A4/CYP3A5 d
    *1A/*3738 (85%)798 (85%)710 (91%)769 (90%)21 (28%)22 (29%)
    *1A/*153 (6%)58 (6%)38 (5%)47 (6%)14 (18%)10 (13%)
    *1B/*158 (7%)73 (8%)24 (3%)31 (4%)32 (42%)40 (53%)
    *1B/*317 (2%)9 (1%)8 (1%)5 (0.6%)9 (12%)4 (5%)
    • a Frequencies are calculated from the total number of samples successfully genotyped for each variant.

    • b All subjects include 8 Hispanics (4 cases and 4 controls) and 2 Asian-Americans (1 cases and 1 control).

    • c Counts are for the number of individuals.

    • d Counts are for the number of haplotypes.

  • Table 2

    Family-based associations between CYP3A4 and CYP3A5 genotypes and risk of prostate cancer among cases and sibling controls

    GenotypeOR (95% CIs), Pa
    No stratificationStratified by disease aggressivenessb
    LowHigh
    CYP3A4
     *1A/*1A1.0 (referent)1.01.0
     All Subjects*1A/*1B or *1B/*1B0.76 (0.48–1.20), 0.240.20 (0.07–0.60), 0.0041.32 (0.77–2.27), 0.31
     Caucasians*1A/*1B or *1B/*1B0.83 (0.48–1.42), 0.490.08 (0.01–0.49), 0.0061.91 (1.02–3.57), 0.04
     African-Americans*1A/*1B or *1B/*1B0.61 (0.27–1.36), 0.230.66 (0.16–2.65), 0.560.49 (0.17–1.43), 0.19
    CYP3A5
     *3/*31.0 (referent)1.01.0
     All Subjects*3/*1 or *1/*10.73 (0.51–1.05), 0.090.45 (0.25–0.82), 0.0091.10 (0.68–1.77), 0.69
     Caucasians*3/*1 or *1/*10.71 (0.49–1.04), 0.080.42 (0.22–0.78), 0.0061.16 (0.70–1.91), 0.56
     African-Americans*3/*1 or *1/*11.00 (0.29–3.52), 1.000.92 (0.10–8.69), 0.940.70 (0.08–5.75), 0.74
    • a Adjusted for age.

    • b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.

  • Table 3

    Family-based associations between CYP3A4 and CYP3A5 haplotypes and risk of prostate cancer among cases and sibling controls

    Haplotype (CYP3A4/CYP3A5)ORs, 95% CIs, Pa
    No StratificationStratified by disease aggressivenessb
    LowHigh
    All Subjects
     *1A/*31.0 (referent)1.01.0
     *1A/*10.90 (0.60–1.34), 0.600.62 (0.33–1.16), 0.131.17 (0.70–1.98), 0.55
     *1B/*10.65 (0.41–1.02), 0.060.22 (0.09–0.53), 0.00071.05 (0.60–1.82), 0.87
     *1B/*32.91 (1.36–6.23), 0.0064.51 (0.64–31.74), 0.133.15 (1.18–8.37), 0.02
    Caucasians
     *1A/*31.01.01.0
     *1A/*10.76 (0.48–1.21), 0.250.62 (0.31–1.25), 0.180.92 (0.51–1.65), 0.77
     *1B/*10.76 (0.44–1.33), 0.340.07 (0.01–0.51), 0.0091.80 (0.95–3.43), 0.07
     *1B/*32.36 (0.85–6.54), 0.103.93 (0.47–32.82), 0.214.18 (0.71–24.79), 0.11
    African-Americans
     *1A/*31.01.01.0
     *1A/*11.24 (0.49–3.18), 0.652.49 (0.29–21.1), 0.400.83 (0.16–4.19), 0.82
     *1B/*10.63 (0.26–1.56), 0.321.80 (0.12–28.0), 0.680.38 (0.09–1.54), 0.17
     *1B/*34.08 (1.35–12.4), 0.01 c 3.05 (1.22–7.61), 0.02
    • a Adjusted for age.

    • b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.

    • c Extremely unstable results due to small sample size.

PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 12 (9)
September 2003
Volume 12, Issue 9
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer
Sarah J. Plummer, David V. Conti, Pamela L. Paris, Anthony P. Curran, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev September 1 2003 (12) (9) 928-932;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CYP3A4 and CYP3A5 Genotypes, Haplotypes, and Risk of Prostate Cancer
Sarah J. Plummer, David V. Conti, Pamela L. Paris, Anthony P. Curran, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev September 1 2003 (12) (9) 928-932;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cancer Predisposition Gene Mutations and Pancreatic Cancer
  • Statin Use and Breast Cancer Risk
  • Tamoxifen and Longitudinal Mammographic Density Change
Show more Short Communications
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement